Enhanced vascular endothelial growth factor signaling in islets contributes to β cell injury and consequential diabetes in spontaneously diabetic Torii rats

Diabetes Research and Clinical Practice

Volumn 106, Issue 2, 2014, Pages 303-311

  Mukai, Eri ^a,b   Ohta, Takeshi ^c   Kawamura, Harukiyo ^a   Lee, Eun Young ^a   Morita, Asuka ^a   Sasase, Tomohiko ^c   Miyajima, Katsuhiro ^c   Inagaki, Nobuya ^b   Iwanaga, Toshihiko ^d   Miki, Takashi ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JAPAN TOBACCO INC   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Islet vasculature; SDT rats; VEGF; VEGFR; Cells

Indexed keywords

INTERLEUKIN 1BETA; SNAKE VENOM; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL LOSS; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE RELEASE; DIABETES MELLITUS; DRUG EFFECT; GLOMERULUS; HYPERGLYCEMIA; IN VIVO STUDY; INFLAMMATION; KIDNEY HEMORRHAGE; MALE; MICROVASCULARIZATION; MOUSE; NONHUMAN; PANCREAS HEMORRHAGE; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BLEEDING; CELL DEATH; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PANCREAS ISLET; PATHOLOGY; PHYSIOLOGY; TRIMERESURUS; VASCULARIZATION;

ANIMALS; CELL DEATH; CROTALID VENOMS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HEMORRHAGE; INSULIN-SECRETING CELLS; INTERLEUKIN-1BETA; ISLETS OF LANGERHANS; MALE; RATS; SIGNAL TRANSDUCTION; TRIMERESURUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84920601878     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.08.023     Document Type: Article

References (32)

1. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. New Engl J Med 2012, 153:44-45.
2. King A.J. The use of animal models in diabetes research. Br J Pharmacol 2012, 166:877-894.
3. Katsuda Y., Ohta T., Miyajima K., Kemmochi Y., Sasase T., et al. Diabetic complications in obese type 2 diabetic rat models. Exp Anim 2014, 64:121-132.
4. Shinohara M., Masuyama T., Shoda T., Takahashi T., Katsuda Y., Komeda K., et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000, 1:89-100.
5. Ohta T., Matsui K., Miyajima K., Sasase T., Masuyama T., Shoda T., et al. Effect of insulin therapy on renal changes in spontaneously diabetic Torii rats. Exp Anim 2007, 56:355-362.
6. Masuyama T., Komeda K., Hara A., Noda M., Shinohara M., Oikawa T., et al. Chronological characterization of diabetes development in male spontaneously diabetic Torii rats. Biochem Biophys Res Commun 2004, 314:870-877.
7. Miki T., Tashiro F., Iwanaga T., Nagashima K., Yoshitomi H., Aihara H., et al. Abnormalities of pancreatic islets by targeted expression of a dominant-negative KATP channel. Proc Natl Acad Sci USA 1997, 94:11969-11973.
8. Mukai E., Fujimoto S., Sato H., Oneyama C., Kominato R., Sato Y., et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2011, 60:218-226.
9. Kawamura H., Li X., Harper S.J., Bates D.O., Claesson-Welsh L. Vascular endothelial growth factor (VEGF)-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of coreceptor binding and deficient regulation of kinase activity. Cancer Res 2008, 68:4683-4692.
10. Masuda Y., Shimizu A., Mori T., Ishiwata T., Kitamura H., Ohashi R., et al. Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol 2001, 159:599-608.
11. Takahashi H., Hattori S., Iwamatsu A., Takizawa H., Shibuya M. A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. J Biol Chem 2004, 279:46304-46314.
12. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312:549-560.
13. Kuroda M., Oka T., Oka Y., Yamochi T., Ohtsubo K., Mori S., et al. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J Clin Endocrinol Metab 1995, 80:3196-3200.
14. Li X., Zhang L., Meshinchi S., Dias-Leme C., Raffin D., Johnson J.D., et al. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 2006, 55:2965-2973.
15. Brissova M., Shostak A., Shiota M., Wiebe P.O., Poffenberger G., Kantz J., et al. Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 2006, 55:2974-2985.
16. Donath M.Y., Boni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 2010, 21:261-267.
17. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
18. Inokuchi C., Ueda H., Hamaguchi T., Miyagawa J., Shinohara M., Okamura H., et al. Role of macrophages in the development of pancreatic islet injury in spontaneously diabetic torii rats. Exp Anim 2009, 58:383-394.
19. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discovery 2007, 6:734-745.
20. Eberhard D., Kragl M., Lammert E. 'Giving and taking': endothelial and beta-cells in the islets of Langerhans. Trends Endocrinol Metab 2010, 21:457-463.
21. Lammert E., Gu G., McLaughlin M., Brown D., Brekken R., Murtaugh L.C., et al. Role of VEGF-A in vascularization of pancreatic islets. Curr Biol 2003, 13:1070-1074.
22. Iwashita N., Uchida T., Choi J.B., Azuma K., Ogihara T., Ferrara N., et al. Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. Diabetologia 2007, 50:380-389.
23. Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013, 273:114-127.
24. Vasir B., Aiello L.P., Yoon K.H., Quickel R.R., Bonner-Weir S., Weir G.C. Hypoxia induces vascular endothelial growth factor gene and protein expression in cultured rat islet cells. Diabetes 1998, 47:1894-1903.
25. Westwell-Roper C.Y., Ehses J.A., Verchere C.B. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction. Diabetes 2014, 63:1698-1711.
26. Fuse M., Yokoi N., Shinohara M., Masuyama T., Kitazawa R., Kitazawa S., et al. Identification of a major locus for islet inflammation and fibrosis in the spontaneously diabetic Torii rat. Physiol Genomics 2008, 35:96-105.
27. Mokhtari D., Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin Sci (Lond) 2009, 118:241-247.
28. Billemont B., Medioni J., Taillade L., Helley D., Meric J.B., Rixe O., et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008, 99:1380-1382.
29. Louvet C., Szot G.L., Lang J., Lee M.R., Martinier N., Bollag G., et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008, 105:18895-18900.
30. Hagerkvist R., Sandler S., Mokhtari D., Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007, 21:618-628.
31. Han M.S., Chung K.W., Cheon H.G., Rhee S.D., Yoon C.H., Lee M.K., et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 2009, 58:329-336.
32. Portha B., Lacraz G., Kergoat M., Homo-Delarche F., Giroix M.H., Bailbe D., et al. The GK rat beta-cell: a prototype for the diseased human beta-cell in type 2 diabetes. Mol Cell Endocrinol 2009, 297:73-85.